<DOC>
	<DOCNO>NCT02800941</DOCNO>
	<brief_summary>Pulmonary hypertension ( PHT ) patient often receive long term oral anticoagulant . If indication strong , secondary chronic thrombo-embolism pulmonary hypertension ( CTE-PHT ) prevention , frequent prescription ( 50 90 % patient ) contrast low level proof PHT . Last least , anticoagulant know principal cause iatrogenic hospitalization ( major bleeding ) . In study , patient follow one year , determine annual frequency major bleeding ( accord International Society Thrombosis Haemostasis ( ISTH ) international definition ) . Each event notify validated independent committee clinical event .</brief_summary>
	<brief_title>Bleeding Frequency Under Anticoagulant Treatment Pulmonary Hypertension</brief_title>
	<detailed_description>Pulmonary hypertension ( PHT ) patient often receive long term oral anticoagulant . If indication strong , secondary chronic thrombo-embolism pulmonary hypertension ( CTE-PHT ) prevention , frequent prescription ( 50 90 % patient ) contrast low level proof PHT . Last least , anticoagulant know principal cause iatrogenic hospitalization ( bleed ) . The one study scale tolerance anticoagulant population find major hemorrhagic level discord clinical practice : really high connective associate pulmonary arterial hypertension ( PAHT ) , low `` simple '' pulmonary embolism CTE-PHT . These discovery could belong methodological failure study : retrospective , monocentric one , without adjudication event independent committee . Furthermore , information existence validate indication anticoagulant treatment . Patients follow one year , determine annual frequency major bleeding ( accord International Society Thrombosis Haemostasis ( ISTH ) international definition ) . Each event notify validated independent committee clinical event .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Patient insure entitle social security scheme ; Patient confirm pulmonary hypertension , follow one three follow center : StEtienne , Grenoble , Lyon ; Pulmonary hypertension among follow etiological diagnosis : idiopathic PAH , PAH associate appetite suppressant , PAH associate connective , Chronic Thromboembolism Pulmonary Hypertension ; Patients receive oral anticoagulant . Impossible following ; Bleeding baseline ; Life expectancy le 3 month ; Pulmonary hypertension Group 2 , Group 3 ( absence associate pulmonary embolism ) Group 5 ( absence associate pulmonary embolism ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pulmonary Arterial hypertension</keyword>
	<keyword>Oral anticoagulant</keyword>
	<keyword>Major bleeding</keyword>
</DOC>